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There is substantial evidence that environmental triggers in combination with genetic and stochastic factors play an
important role in spontaneous autoimmune disease. Although the specific environmental agents and how they
promote autoimmunity remain largely unknown, in part because of diverse etiologies, environmentally induced
autoimmune models can provide insights into potential mechanisms. Studies of idiopathic and environmentally
induced systemic autoimmunity show that they are mediated by common adaptive immune response genes. By
contrast, although the innate immune system is indispensable for autoimmunity, there are clear differences in the
molecular and cellular innate components that mediate specific systemic autoimmune diseases, suggesting distinct
autoimmune-promoting pathways. Some of these differences may be related to the bifurcation of toll-like receptor
signaling that distinguishes interferon regulatory factor 7-mediated type I interferon production from nuclear
factor-κB-driven proinflammatory cytokine expression. Accordingly, idiopathic and pristane-induced systemic
autoimmunity require both type I interferon and proinflammatory cytokines whereas the less aggressive mercury-
induced autoimmunity, although dependent on nucleic acid-binding toll-like receptors, does not require type I
interferon but needs proinflammatory cytokines. Scavenger receptors and the inflammasome may contribute to
silica-induced autoimmunity. Greater understanding of the innate mechanisms responsible for idiopathic and
environmentally induced autoimmunity should yield new information into the processes that instigate and drive
systemic autoimmunity.
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Immunity requires contributions from both the innate
and adaptive arms of the immune system. The innate
component, found in all classes of plant and animal life,
is hard-wired to recognize and respond rapidly to patho-
gens, but does not confer long-lasting or protective im-
munity [1]. In mammals, it is essential for the activation
of the evolutionarily younger adaptive immune response
[2], which, unlike the innate system, can be modified to
generate highly specific antibodies and T cells capable
of targeting virtually all foreign antigens. Adaptive im-
munity also mediates immunological memory, which fa-
cilitates faster, more effective responses to previously
encountered antigens. Under normal circumstances, the
immune system protects against infectious organisms,* Correspondence: mpollard@scripps.edu
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distribution, and reproduction in any mediumrequiring it to distinguish foreign agents, including vi-
ruses, bacteria, fungi and parasites, from the host's
healthy tissues. Failure to distinguish foreign from host,
however, can result in the development of autoimmune
diseases, including organ-specific disease with restricted
tissue involvement, such as multiple sclerosis and type I
diabetes, or more systemic involvement such as systemic
lupus erythematosus (SLE). For most idiopathic auto-
immune diseases, components of both the innate and
adaptive immune responses are needed [3-5]. To varying
extents, environmental factors also contribute to the de-
velopment of autoimmunity. However, although idiopathic
and environmentally induced systemic autoimmunity
share common requirements [6,7], it is becoming clear
that differences exist [8]. In this review we compare and
contrast the innate immune system requirements for idio-
pathic systemic autoimmunity with systemic autoimmun-
ity induced by exposure to mercury and pristane. We also
discuss the innate immune components in silica-inducedntral Ltd. This is an Open Access article distributed under the terms of the
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induced autoimmunity.
Innate immunity
The innate immune response provides an immediate
response to infection and injury and is mainly mediated
by circulating factors and non-lymphocytic cell types
that include macrophages, dendritic cells (DCs), neu-
trophils and other less common leukocytes. Surveil-
lance mechanisms involve secreted, cell surface and
intracellular pattern recognition receptors, such as toll-
like receptors (TLRs), NOD-like receptors and RIG-I-
like receptors [4,9]. Pattern recognition receptors
respond not only to pathogen-associated molecular
patterns, including bacterial and viral nucleic acids,
lipoproteins and carbohydrates, but also to host-derived
damage-associated molecular patterns such as ATP, high-
mobility group box 1 and self-DNA. The recognition by
pattern recognition receptors of these pathogen-
associated molecular patterns and/or damage-associated
molecular patterns results in cell signaling and activation
of transcription factors such as NF-κB and IFN regulatory
factors (IRFs) [10]. The resulting gene expression includes
cytokines and chemokines, leading to inflammatory cell
recruitment and activation, and expression of co-
stimulatory molecules crucial for the induction of adaptive
immunity [2].
Innate immunity in idiopathic systemic autoimmunity
Systemic autoimmunity is thought to result from a mix of
genetics, environmental factors and stochastic events [6].
Given the multitude of susceptibility genes, symptoms and
immunological abnormalities, it is clear that numerous
pathogenic pathways contribute to systemic autoimmune
disease [5,11,12]. A major thrust of systemic autoimmun-
ity research has centered on elucidation of abnormalities
in the adaptive immune response [13,14]. However more
recent research has identified the innate immune response
as a major player in the initiation and expansion of sys-
temic autoimmune pathology [4,5,9,15,16].
The current paradigm for the disease process of idio-
pathic systemic lupus-like autoimmunity argues for a
central role of type I IFN [15,17,18]. This is based on the
early observation of increased expression of IFN-α
inducible genes (or IFN signature) in the peripheral
blood cells of patients with SLE [17]. The type I IFN sig-
nature is found in 60% to 70% of patients with SLE,
dermatomyositis, polymyositis or systemic sclerosis [19]
but less frequently in patients with rheumatoid arthritis
or multiple sclerosis [20]. The central role of type I IFN
in SLE places special focus on the role of cells of the in-
nate immune system, especially DCs [9,15,21]. DCs
can be divided into three categories, conventional,
plasmacytoid (pDC) and monocyte-derived [22]. DCs actas antigen presenting cells, are migratory and can con-
trol T cell responses [23]. Upon stimulation, pDCs pro-
duce large amounts of type I IFN in humans and mice
and they are considered the main source of type I IFN in
systemic autoimmunity [24]. Deletion of DCs, including
pDCs, in lupus-prone MRL-Faslpr mice reduces disease
severity including lymphocyte expansion, anti-chromatin
autoantibodies and glomerulonephritis [25]. Most sig-
nificantly, lupus-predisposed mice lacking pDCs due to
the absence of IRF8 or showing pDC-specific defects in
type I IFN production due to mutation of peptide/histi-
dine transporter solute carrier family 15, member 4 do
not develop autoimmunity [26]. These recent findings
implicate pDCs and their ability to produce type I IFN
as major contributors to the pathogenesis of lupus.
The important role that monocytes and macrophages
play in phagocytosis, cytokine production and antigen
presentation has also identified them as influential
players in the innate immune response in systemic auto-
immunity [27]. Deficiency of colony-stimulating factor-1,
the principal growth factor for macrophages, in MRL-
Faslpr mice reduces disease severity [28]. Deficiency of
macrophage migration inhibitory factor reduces macro-
phage recruitment and glomerulonephritis in MRL-
Faslpr mice [29]. Cultured in the presence of serum,
macrophages from MRL-Faslpr mice have dysregulated
gene expression compared with non-lupus-prone mice
[30]. The presence of the complement component C1q
also enhances immune-complex-mediated gene expres-
sion in monocytes of patients with SLE [31]. C1q prefer-
entially promotes binding of immune complexes to
monocytes rather than pDCs and thus indirectly reduces
type I IFN production by pDCs [32]. The ability of C1q
to suppress type I IFN may be an additional reason that
C1q deficiency enhances susceptibility to SLE [33].
Type I IFN plays a significant role in the onset and se-
verity of idiopathic autoimmunity. Induction of type I
IFN by TLR3 and melanoma differentiation-associated
protein-5 agonist, polyinosinic:polycytidylic acid (poly
(I:C)), exacerbates idiopathic systemic autoimmunity, par-
ticularly nephritis, in C57BL/6-Faslpr [34], NZW hybrid
[35] and NZB/NZWF1 [36] mice. Moreover sustained
production of type I IFN by injection of adenovirus-
expressing IFN-α also exacerbates disease, including
glomerulonephritis in idiopathic lupus models [37-40].
By contrast, deficiency of type I IFN receptor (IFNAR)
reduces disease severity in most autoimmune models
[41,42] except MRL-Faslpr, where absence of IFNAR
leads to more severe disease [43] and antibody blocking
of the IFNAR has minimal beneficial effect [44]. The
mechanism whereby IFNAR deficiency exacerbates disease
in MRL-Faslpr mice is unknown, however, deletion of DCs
(including pDCs) in this model while still allowing
T and B cell activation, hypergammaglobulinemia and
Pollard and Kono BMC Medicine 2013, 11:100 Page 3 of 12
http://www.biomedcentral.com/1741-7015/11/100anti-nucleolar autoantibodies (ANoA) does substantially
reduce disease severity [25], suggesting that DCs are re-
quired for promoting autoimmune disease by mechanisms
beyond the production of type I IFN.
Type I IFN expression relies on activation of TLRs
and signaling via IRF7 [4,45]. Numerous studies have
determined that endosomal TLRs, particularly TLR7
and TLR9, influence idiopathic systemic autoimmunity
[46-49]. However, specific endosomal TLRs make differ-
ent contributions to disease severity. Loss of TLR3 does
not impact disease [50] although TLR3 stimulation of
myeloid differentiation factor 88 (MyD88)-deficient
mice, which lack TLR7 and TLR9 signaling, partially re-
covers disease [51]. Absence of TLR7 partially amelio-
rates disease [52-54] whereas deficiency of TLR9
exacerbates autoimmunity in a TLR7-dependent manner
[52,53]. The 'triple D' mutation in Unc-93 homolog B1
(Unc93b1), an integral component of endoplasmic
reticulum, involved in the trafficking of TLR3, TLR7 and
TLR9 [55,56], abolishes endosomal TLR signaling [55]
and suppresses disease in lupus-prone C57BL/6-Faslpr,
BXSB [46] and MRL-Faslpr (Koh YT et al, J. Immunol. In
press).
All TLR signaling pathways lead to activation of the tran-
scription factor NF-κB and production of proinflammatory
cytokines (for example, IL-1, IL-6, TNFα) [4,57,58]. Accord-
ingly, modulation of certain individual proinflammatory cy-
tokines can have significant effects on the expression of
idiopathic autoimmunity. For example, treatment with anti-
IL-6 or anti-IL-6 receptor antibody results in reduced
severity of kidney damage in lupus-prone mice [59,60]
whereas recombinant IL-6 exacerbates glomerulonephritis
[61]. Complete deficiency of IL-6 in MRL-Faslpr mice
reduces clinical, immunological and histological indices of
lupus and improves survival [62]. IL-1, which consists of α
and β forms [63], is elevated in idiopathic lupus models
[64,65]. Treatment with recombinant IL-1 receptor [66] re-
duces the severity of systemic autoimmunity as does IL-1
receptor antagonist [67], although the latter appears not to
be effective against established disease [68]. The contribu-
tions of the separate α and β forms of IL-1 remain to be
determined. The role of another proinflammatory cytokine,
TNFα, in systemic autoimmunity is less clear. Treatment
with TNFα increases survival in lupus-prone mice [69,70]
and loss of Tnf [71] or Tnf receptors [72] accelerates
disease. By contrast, treatment with anti-TNF receptor
increases survival [73].
hese studies show that innate immune responses
contribute significantly to disease severity in idiopathic
systemic autoimmunity. Principal contributions, identi-
fied to date, come from pDCs and TLR- or IRF7-
mediated type I IFN production. However it is clear that
proinflammatory cytokines, especially IL-6, expressed by
TLR or NF-κB signaling also play a significant role. Inaddition early components of the complement cascade
are protective.
Innate immunity in environmentally induced systemic
autoimmunity
That systemic autoimmunity can be elicited by exogen-
ous factors, especially medications, is well established in
both humans and animal models [6,74,75]. These can
trigger disease in individuals with or without susceptibil-
ity to idiopathic autoimmunity or can lead to enhance-
ment of existing autoimmune disease. However, these
observations come with two clear caveats. First, there
are no accepted criteria for diagnosis or classification of
environmentally associated autoimmunity in humans,
nor are there criteria that distinguish environmentally
associated autoimmunity from types of idiopathic auto-
immune diseases [76]. Second, although studies of ani-
mal models have provided critical understanding of
many facets of human systemic autoimmunity [12], they
are limited by incomplete representation of the full
spectrum of human disease [77]. Nonetheless, common
mechanisms of adaptive immunity exist for both induced
and idiopathic disease in human and animals including
loss of tolerance, T and B cell activation and autoantibody
production [6,78]. However, the role that innate immunity
plays is only beginning to be examined. Exposure to envir-
onmental agents such as mercury [79-81], crystalline silica
[82,83] and pristane [84] are known to result in a lupus-
like systemic autoimmunity in animal models. Although
the mechanisms of induction are poorly understood, pub-
lished as well as our preliminary studies suggest that spe-
cific environmental triggers induce or modulate systemic
autoimmunity through distinct components of the innate
immune system.
Pristane
Pristane, also known as 2,6,10,14-tetramethylpentadecane
(or TMPD), is a component of mineral oil that induces
chronic inflammation and plasmacytomas in mice [85]. In
humans, mineral oil or petroleum waste has been associ-
ated with rheumatoid arthritis and possibly lupus [84]. In
susceptible strains of mice, pristane injection causes a
lupus-like disease characterized by a wide spectrum of pri-
marily antinuclear autoantibodies (ANA) and immune
complex-mediated glomerulonephritis [84]. Severity of
disease including IgG autoantibodies and glomeruloneph-
ritis are reduced in the absence of IFN-γ [86], IL-6 [87]
and IL-12p35 [88]. Pristane-induced autoimmunity may
also fall under a common syndrome called ASIA (auto-
immune syndrome induced by adjuvants) [89].
Similar to SLE, pristane-induced autoimmunity is associ-
ated with increased expression of type I IFN-inducible
genes in peripheral blood cells (IFN signature) [90,91]. The
most severe aspects of disease are dependent on type I IFN;
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pristane exhibit markedly reduced lupus-specific autoanti-
bodies, proteinuria and glomerular hypercellularity [92].
Type I IFN expression, autoantibody production and glom-
erulonephritis in pristane-treated mice are primarily medi-
ated via a TLR7- and MyD88-dependent pathway [93,94].
In addition, deficiencies in TLR4 and TLR9 also impact dis-
ease severity [95]. Interestingly, TLR deficiency differentially
affects lupus-specific autoantibody production, with ab-
sence of TLR7 or TLR9 reducing anti-ribonucleoprotein re-
sponses but not anti-DNA [94,95] whereas lack of TLR4
reduced production of both anti-ribonucleoprotein and
anti-DNA autoantibodies [95]. Pristane-treated Ifnar−/−
mice also have reduced expression and activation of TLR7
and TLR9 in B cells [96], suggesting a positive feedback
mechanism in which type I IFN augments TLR-mediated B
cell responses. In contrast to spontaneous lupus, type I IFN
production in pristane-induced autoimmunity is not
dependent on DCs, but is produced by immature Ly6Chigh
inflammatory monocytes [97]; increases in Ly6Chigh mono-
cyte numbers correlates with greater amounts of lupus-
specific autoantibodies [97]. Type I IFN is also required for
the chemokine expression necessary for recruitment of in-
flammatory monocytes [98], which likely results in a posi-
tive feedback signal and further acceleration of IFN
production. This expansion of monocytes by type I IFN ap-
pears to be relatively specific because the lack of the inflam-
matory cytokines TNF-α, IL-6, IL-1 [98] and IFN-γ, which
are required for disease [84], have no effect on Ly6Chigh
monocyte recruitment.
The chronic inflammatory response to pristane also
includes neutrophil infiltration, which in contrast to
monocytes requires IL-1, specifically IL-1α, and is medi-
ated by MyD88 and IL-1 receptor-associated kinase, but
not IRF7 [99]. IL-1β, caspase 1 and the inflammasome
components NOD-like receptor family, pyrin domain
containing 3 (NLRP3) and apoptosis-associated speck-
like protein containing a CARD (ASC) (which are re-
quired for caspase 1 activation [100]) are not required
for neutrophil recruitment in pristane-induced chronic
inflammation [99]. Although IL-1alpha; has not been dir-
ectly linked to the autoimmunity elicited by pristane, it
does induce expression of IL-6 [101], which is required for
pristane-induced hypergammaglobulinemia and the pro-
duction of anti-DNA and anti-chromatin [87].
The protein product of IRF5, a lupus susceptibility
gene [102], acts as a transcription factor to mediate TLR
induction of proinflammatory cytokines IL-6, IL-12,
TNFα and, to some extent, IFN-α, independent of
NF-κB [103-105]. Notably, Irf5 deficiency reduced
pristane-induced disease severity including the expan-
sion of Ly6Chigh monocytes, type I IFN signature, auto-
antibodies and renal disease [106-109]. This was
confirmed in pure Irf5-deficient mice lacking aspontaneous Dock2 mutation found in some Irf5 knock-
out lines that alters pDC and B cell development and
type I IFN production [108-110].
These studies suggest that disease expression and se-
verity in the pristane model are tightly linked to nucleic
acid-sensing TLR and MyD88 signaling leading to type I
IFN production analogous to idiopathic lupus. Unlike
idiopathic lupus, however, type I IFN production is pro-
duced by immature monocytes rather than pDCs. By
contrast, although a feature of this model is chronic in-
flammation, inflammasome components and IL-1β ap-
pear to play little if any role.
Mercury
Exposure to mercury in humans has been associated
with autoimmune manifestations in small surveys, but
more definitive large-scale epidemiological studies are
lacking [111]. Studies of South American gold miners
documented that mercury exposure was associated with
higher levels of proinflammatory cytokines (IFN-γ,
TNF-α, IL-1β) and autoantibodies [80,112]. In other
studies, mercury exposure from skincare products was
associated with membranous nephropathy [79,113].
Thus, although only limited human populations at po-
tential risk for mercury-induced autoimmunity have
been studied in detail [75,113], the severity of systemic
disease that was induced by mercury exposure appears
mild compared to that of idiopathic SLE.
Possible mechanisms for mercury-induced systemic
autoimmunity have come largely from studies of suscep-
tible mice and rats that, when exposed to mercury, de-
velop lymphocyte activation, ANA and deposits of
immune complexes in blood vessels and glomeruli [77].
The adaptive immune responses required for murine
mercury-induced autoimmunity (mHgIA) share com-
mon requirements with idiopathic lupus including cer-
tain cytokines [114,115], co-stimulation factors [116,117]
and transcription factors [8,118]. However, whereas type
I IFN signaling pathways predominate in idiopathic and
pristane-induced autoimmune disease, our recent studies
indicate that mHgIA is independent of type I IFN. Ac-
cordingly, Ifnar1-deficient C57BL/6, NZB and BXSB
mice all have similar autoimmune responses to mercury
exposure as wild-type mice (Kono and Pollard, unpub-
lished observations), in contrast to the known type I
IFN-dependence of spontaneous autoimmunity in both
NZB and BXSB strains [41,44]. This lack of dependence
on type I IFN is further supported by the observation
that mercury-induced hypergammaglobulinemia and
autoantibodies in Inept mice, which are deficient in
IRF7 and consequently do not produce IFN-α after
TLR7 or TLR9 stimulation [119], are not reduced com-
pared to the wild-type (Kono and Pollard, unpublished
observations).
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autoimmunity [93-95], severity of mHgIA is impacted by
TLR activation because the TLR4 ligand lipopolysacchar-
ide exacerbates disease [120]. Although the specific
TLRs required for mHgIA remain to be examined,
mercury-exposed autoimmune-prone BXSB mice with
the triple D mutation in Unc93b1 (required for
endosomal TLR3, TLR7 and TLR9 signaling [121]) do
not develop ANA or increased serum IgG unlike wild-
type BXSB (Kono and Pollard, unpublished observa-
tions). Thus, although endosomal TLRs contribute to
mHgIA, type I IFN is not required in both autoimmune-
prone and healthy genetic backgrounds. It is possible
that mercury exposure can replace type I IFN by activat-
ing the IFNAR pathway or related genes downstream of
IFNAR activation. Alternatively, mHgIA may not be me-
diated by type I IFN. Related to this, our preliminary
studies show that mercury exposure suppresses IFN-
.alpha; induction mediated by poly(I:C) (TLR3 agonist)
while proinflammatory cytokine (for example, IL-6) pro-
duction is unaffected (Kono and Pollard, unpublished
observations). This supports the latter possibility that
mHgIA is not mediated by type I IFN and may also ex-
plain why mHgIA is a relatively mild disease compared
to idiopathic lupus [19,80]. It remains to be determined,
however, if mHgIA can be exacerbated by exogenous
type I IFN. The lack of dependence on type I IFN but re-
quirement for endosomal TLRs is similar to spontaneous
lupus in the MRL background [43,53].
Endosomal TLR signaling leads to cell activation and
to type I IFN production via IRF7 and the induction of
proinflammatory cytokines IL-6, pro-IL-1β and TNF-α
via the NF-κB pathway [4,122-124]. Dependence on
endosomal TLRs but not Irf7 or Ifnar suggests that
mHgIA may be primarily mediated by NF-κB signaling
[4]. IL-1 signaling also activates NF-κB [101] and we
have shown that cell bound IL-1α is required for
mercury-induced T cell proliferation in vitro [125],
suggesting that cell signaling via the IL-1 receptor may
also be important for mHgIA. We have, however, shown
that neither NLRP3 nor caspase 1 deficiency impacts ex-
pression of mHgIA [8], suggesting that IL-1β is not
required. In other experiments, we also examined the
effects of IL-6, which is induced by NF-κB [101],
on mHgIA and found B10.S-Il6−/− mice exposed to
HgCl2 had reduced serum IgG autoantibodies and
kidney deposits of IgG compared to wild-type mice
[126]. Although the pathways have yet to be defined,
taken together, these studies point to the endosomal
TLRs, the proinflammatory cytokines IL-1α and IL-6
but not type I IFN as the major innate factors that
drive autoimmunity following exposure to mercury.
Furthermore, NF-κB-associated pathways, but not
IRF7 were implicated.Silica
Silica exposure is common in mining, sandblasting,
rock drilling, granite cutting, construction work, brick-
laying and cement work. In 2007, the US Occupational
Safety and Health Administration estimated that almost
two million individuals in the USA are occupationally
exposed to respirable crystalline silica [127] and expos-
ure continues to be a national and worldwide problem
[128]. Inhalation of crystalline silica can cause silicosis,
which is characterized by chronic inflammation and
scarring in the upper lobes of the lungs [128]. Addition-
ally, epidemiologic data have repeatedly associated silica
exposure with systemic autoimmunity [111] includ-
ing SLE, rheumatoid arthritis and systemic sclerosis
[83,111,129-131]. Notably, silica dust exposure is asso-
ciated with high titers of ANA [132] and both the pres-
ence of autoantibodies and clinical symptoms are
positively correlated with intensity (that is, concentra-
tion and frequency) of exposure [133,134]. Further sup-
port has come from animal models in which lupus in
susceptible mice is exacerbated by exposure to silica
[135,136] and ANAs develop in non-autoimmune mice
and rats exposed to silica products [137,138]. The
mechanisms mediating silica-induced autoimmunity are
not yet defined. Nevertheless, one possibility is that the
chronic inflammatory milieu present in silicosis might
induce or exacerbate autoimmunity through the pro-
duction of proinflammatory cytokines and release of
self-antigens [139-141].
Silica-induced inflammation is mainly caused by the
toxic effects of silica on alveolar macrophages, resulting
in the release of proinflammatory chemokines and cyto-
kines including TNF and IL-1 [128,142], and the influx
of neutrophils, macrophages, DCs and lymphocytes
[143-145]. Silica-induced pulmonary inflammation is
dependent on IFN-γ [146] but not Th2 cytokines such
as IL-4 and IL-13 [147], or IL-12 [148], requirements
similar to those of mHgIA [8,114]. Innate immunity me-
diates this process as silica-induced inflammation and fi-
brosis can occur in the absence of T, B, NKT or NK
cells [143]. Notably, although acute lung inflammation
requires IL-17 [149], chronic inflammation is dependent
on type 1 IFN and IRF7 [150]. NALP3 (NACHT, LRR
and PYD domains-containing protein 3) inflammasome
components, caspase-1 and IL-1β, are also required for
silicosis [142,151-153] and our preliminary findings indi-
cate that caspase-1 is required for autoantibody induc-
tion (Kono and Pollard, unpublished observations).
Although the role of individual TLRs has not been ex-
amined, silica has been shown to suppress TLR-
mediated activation of DCs [144], but its effect on TLR
stimulation of alveolar macrophages, the primary cell-
type responsible for inflammasome-mediated lung in-
flammation [142], is not known. Death of alveolar
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mation and autoimmunity by impairing the clearance
of silica and apoptotic cells, and by generating apop-
totic material. In support of this, deficiency of either
scavenger receptors macrophage receptor with a collag-
enous structure (MARCO) or CD204, expressed mainly
on macrophages, was shown to impair silica clearance
and exacerbate silica-induced lung inflammation
[154,155]. Additionally, MARCO-deficient mice are de-
fective in clearing apoptotic cells [156] and both
MARCO and CD204 have been argued to promote tol-
erance to apoptotic cell material [157]. These observa-
tions suggest that scavenger receptor-mediated uptake
of silica and subsequent macrophage cell death may ad-
versely affect clearance of dead and dying cells, which,
in turn, could impact self-tolerance [158,159] and pro-
mote autoimmunity.
Studies with silica-induced lung inflammation, while
only indirectly implying mechanisms of silica-induced
autoimmunity, suggest that, like idiopathic lupus and
pristane-induced autoimmunity, innate mechanisms in-
volving IRF7 and type I IFN might play pivotal roles.
Silica-induced killing of scavenger receptor-bearing mac-
rophages, inflammasome activation and IL-1β are also
likely to make significant contributions. The require-
ment for the inflammasome pathway is clearly different
from the innate immune responses required for the de-
velopment of pristane-induced autoimmunity [84,99]
and mHgIA [8].
Innate immune mechanisms contributing to
environmentally induced autoimmunity
As is clear from the studies discussed above, innate im-
munity plays an essential role in both idiopathic and
environmentally induced lupus-like autoimmunity, with
the requirement for endosomal TLRs and/or Unc93b1
providing a unifying mechanism for idiopathic and
pristane- and mercury-induced disease [4]. Signaling by
these TLRs leads to cell activation and the production
of proinflammatory cytokines via NF-κB and type I
IFNs by IRF7 activation [4]. By contrast, as presented
above, different innate pathways have been implicated
in the development of pristane-, mercury- and silica-
induced autoimmune diseases that mediate the induc-
tion of inflammation, cell death, the adaptive response
and autoimmunity, supporting our contention that en-
vironmental factors can induce or enhance lupus-like
autoimmunity through several different innate mecha-
nisms. How the different innate responses are elicited
and how they consequently promote autoimmunity re-
mains to be determined. However, a few possible expla-
nations can be postulated.
Recent studies suggest that adaptor protein complex 3
(AP-3), which is involved in the sorting of transmembraneproteins to lysosomes and lysosome-related organelles
(LRO), may bifurcate these signaling pathways because
AP-3 is required for TLR7 and TLR9 induction of type
I IFN but not proinflammatory cytokines [56]. AP-3
mediates trafficking of TLRs and UNC93B1 to the
lysosome-associated membrane protein 2+ (LAMP2+)
late endosomes and LROs but not to vesicle-associated
membrane protein 3+ (VAMP3+) early endosomes
[4,56]. Thus UNC93B1-mediated endosomal TLR traffick-
ing moves to early endosomes in an AP-3 independent
manner, leading to NF-κB-regulated proinflammatory
cytokine production (NF-κB endosome), and then in an
AP-3 dependent step to late endosomes/LRO and IRF7-
mediated type I IFN production (IRF7 endosome) [4]. The
importance of endosomal location in DC responses has
been shown by studies using different classes of CpG
oligonucleotide ligands to stimulate TLR9 signaling
[160-162]. In addition, viperin, a component of endoplas-
mic reticulum-derived lipid storage granules or lipid bod-
ies, is required for endosomal TLR-mediated type I IFN
by pDCs but does not contribute to proinflammatory
cytokine production in pDCs or type I IFN production by
other cell types [163]. Viperin may thus be central to the
role of pDCs and type I IFN production in systemic
autoimmunity.
The bifurcation of TLR trafficking and signaling regu-
lated by AP-3 may explain the dependence of mHgIA on
Unc93b1 and proinflammatory cytokines like IL-6 as
well as its type I IFN independence. Mercury is known
to accumulate in lysosomes [164,165] and may thus im-
pact AP-3 controlled TLR trafficking to the IRF7 endo-
some, leading to reduced type I IFN production. Silica
can also affect lysosomal function, particularly in macro-
phages [166,167], suggesting that silica-induced auto-
immunity may also be influenced by effects on lysosome
function. We can find no evidence that pristane affects
lysosome function, however given the type I IFN-
dependence of pristane-induced autoimmunity [92], we
expect pristane not to hamper TLR trafficking and/or
signaling.
In Figure 1 we outline our view of the mechanisms of
innate immunity in environmentally induced auto-
immunity with emphasis on the contribution of bifur-
cation of TLR signaling to mHgIA. We propose that the
toxic response to mercury [168], pristane [169] or silica
[170] leads to the availability of nucleic acid/protein self-
antigens. These are then brought into the endolysosomal
machinery of antigen presenting cells such as DCs, mac-
rophages and/or B cells where they complex with TLRs
and traffic to early endosomes (NF-κB endosome), lead-
ing to NF-κB-regulated proinflammatory cytokine pro-
duction. IRF7-mediated type I IFN production via late
endosomes/LRO (IRF7 endosome) has little role in
mHgIA as suggested by the failure of Ifnar and Irf7
Figure 1 Innate immune mechanisms contributing to environmentally induced autoimmunity. The toxic response to environmental
agents results in self nucleic acid/protein complexes that may become ligands for endosomal TLRs via scavenger receptors, particularly in
macrophages. UNC93B1-mediated trafficking of endosomal TLRs leads first to VAMP3+ early endosomes, where signaling results in NF-κB
activation and proinflammatory cytokine production. TLRs, again in concert with Unc93b1, also traffic to LAMP2+ LROs where IRF7 is activated to
stimulate type I IFN expression. Lipid bodies, which contain components of the TLR signaling complex, may contribute to type I IFN particularly in
pDCs. Activation of IRF5 in complex with TRAF6 can lead to proinflammatory cytokine production. NF-κB-mediated proinflammatory cytokine
production may be augmented by release of constitutively expressed IL-1α from dead and dying cells. IL-1α may also contribute to adaptive
immunity via differentiation and expansion of CD4+ T cells and enhanced expression of IFN-γ-stimulated genes such as IRF1. The large box
signifies signaling events in innate immune responses that may occur in one or more cell types. Steps required for mHgIA are shown in
rectangles with a thick black line while those not required are shown by ovals with a broken line. Steps required for pristane-induced
autoimmunity include those leading to type I IFN and proinflammatory cytokine production and may also include pathways involving IL-1α,
particularly IL-1α-driven NF-κB activation. AP-3, adaptor protein complex 3; Hg, mercury; IFN, interferon; IFNAR, type I IFN receptor; IL, interleukin;
IRF, interferon regulatory factors; LAMP2, lysosome-associated membrane protein 2; LRO, lysosome-related organelle; NF, nuclear factor; Si, silica;
Th1, T helper type 1; TLR, Toll-like receptor; TNF, tumor necrosis factor; TRAF6, TNF receptor associated factor 6; UNC93B1, Unc-93 homolog B1;
VAMP3, vesicle-associated membrane protein 3.
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the mercury-induced NF-κB-mediated inflammatory
response is likely aided by IL-1α from dead and dying
cells. IL-1α is also important for mercury-induced T cell
proliferation [125] and may contribute to enhanced CD4+
T cell expansion and differentiation [171]. In addition,
IL-1α synergizes with IFN-γ to regulate IFN-γ induced
gene expression in an NF-κB-dependent manner [172],
thus linking the innate and adaptive responses in mHgIA.
Interestingly, IL-1α, released from dying cells, can initi-
ate sterile inflammation involving neutrophils [173],
supporting its role in granulocyte recruitment in
pristane-induced chronic inflammation [99]. We would
argue that, unlike pristane, mHgIA may not require
NF-κB independent proinflammatory cytokine produc-
tion mediated by IRF5, particularly as IRF5 requires TNFreceptor-associated factor 6 (TRAF6) [103], which is a
component of the signaling complex of lipid bodies [4].
Conclusions
Innate immunity plays an essential role in both idio-
pathic and environmentally induced autoimmunity, how-
ever there are clear differences in the required molecular
and cellular components that mediate disease develop-
ment. In idiopathic autoimmunity, both type I IFN and
proinflammatory cytokines are needed for disease with
pDCs being the primary cells involved in type I IFN pro-
duction. By contrast, in pristane-induced autoimmunity,
TLR/MyD88 signaling, leading to type I IFN and
proinflammatory cytokines, does not require DCs, but
rather immature monocytes. Mercury-induced auto-
immunity, although showing clear evidence of TLR
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http://www.biomedcentral.com/1741-7015/11/100involvement does not require type I IFN, but rather
shows significant dependence on proinflammatory cyto-
kines such as IL-1α and IL-6. Additional pathways may
apply to silica-induced autoimmunity as scavenger re-
ceptors and the inflammasome are central to silica-
induced inflammatory responses. It can be speculated
that some of these differences may be related to the bi-
furcation of TLR signaling that distinguishes IRF7-
mediated type I IFN production and NF-κB-driven
proinflammatory cytokine expression. These findings
from several environmentally induced models suggest
that environmental triggers can induce autoimmunity
through diverse innate pathways. A greater understand-
ing of the specific innate processes that initiate or ex-
acerbate disease will be key to understanding the role of
environmental factors in autoimmunity.
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